Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
17.10. | Lobe Sciences Ltd (2): Lobe Sciences hires Enclave, Peak for financing | 1 | Stockwatch | ||
02.10. | Lobe Sciences Ltd (2): Lobe Sciences receives U.S. patent for psilocin mucate | 4 | Stockwatch | ||
13.08. | Lobe Sciences Ltd (2): Lobe Sciences directors Young, Phillips resign | 1 | Stockwatch | ||
04.06. | Lobe Sciences Ltd (2): Lobe Sciences talks uplisting possibilities | 1 | Stockwatch | ||
03.06. | Lobe Sciences Ltd (2): Lobe Sciences appoints Ramjeet as director | 1 | Stockwatch | ||
31.05. | Lobe Sciences Ltd (2): Lobe Sciences appoints Sancilio to board of directors | 1 | Stockwatch | ||
30.05. | Lobe Sciences Ltd (2): Lobe Sciences appoints Jacobson to board of directors | 1 | Stockwatch | ||
21.05. | Lobe Sciences Ltd (2): Lobe Sciences holder Clearway's ownership exceeds 50% | 20 | Stockwatch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CORE ONE LABS | 0,079 | -100,00 % | XFRA LD6: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCORE ONE LABS INC.... ► Artikel lesen | |
BIONXT SOLUTIONS | 0,163 | -1,22 % | BioNxt reicht Patentanmeldungen auf nationaler Ebene für sublinguale Krebsmedikamente zur Behandlung von neurodegenerativen Autoimmunerkrankungen ein | VANCOUVER, BC / ACCESSWIRE / 29. Oktober 2024 - BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE: BNXT / OTCQB: BNXTF / FWB: BXT) freut sich bekannt zu geben, dass das Unternehmen ein... ► Artikel lesen | |
AMYRIS | - | - | BioMaP-Consortium Contracts Amyris to Support Domestic Medicines Supply | ||
ATAI LIFE SCIENCES | 0,978 | -1,94 % | ATAI Life Sciences N.V. - 8-K, Current Report | ||
REVIVE THERAPEUTICS | 0,001 | 0,00 % | Revive Therapeutics Ltd: Revive expects bucillamine study results by year-end | ||
CYBIN | 9,250 | -0,54 % | CYBIN INC. - 6-K, Report of foreign issuer | ||
SOL GLOBAL INVESTMENTS | 0,088 | +12,10 % | SOL Global Investments Corp.: SOL Global Announces Strategic Change with Investment Focus in Solana | Toronto, Ontario--(Newsfile Corp. - November 4, 2024) - SOL Global Investments Corp. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB) ("SOL" or "the Company") today announced a strategic shift by its wholly-owned... ► Artikel lesen | |
AWAKN LIFE SCIENCES | 0,053 | -12,40 % | Awakn Life Sciences Corp.: Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites | Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing... ► Artikel lesen | |
RAPID DOSE THERAPEUTICS | - | - | Rapid Dose Therapeutics Corp.: Rapid Dose Announces Closing of Final Tranche of Common Share Private Placement | Burlington, Ontario--(Newsfile Corp. - October 30, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") is pleased to announce that it has closed a second and final tranche of... ► Artikel lesen | |
EVOTEC | 8,500 | +4,94 % | Aixtron, Evotec, HelloFresh, Nel ASA, Schalke 04, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
QIAGEN | 39,940 | -0,57 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen | QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen // Mithilfe... ► Artikel lesen | |
ARCELLX | 87,01 | +0,64 % | Arcellx meldet vielversprechende Ergebnisse für Myelom-Behandlung | ||
ARCUTIS BIOTHERAPEUTICS | 9,300 | +6,65 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 35,940 | +4,33 % | Edgewise Therapeutics shares maintain price target on positive data | ||
HARMONY BIOSCIENCES | 33,410 | +1,01 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen |